These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19147221)

  • 1. The effect of a hydroxamic acid-containing polymer on active matrix metalloproteinases.
    Skarja GA; Brown AL; Ho RK; May MH; Sefton MV
    Biomaterials; 2009 Apr; 30(10):1890-7. PubMed ID: 19147221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMP levels in the response to degradable implants in the presence of a hydroxamate-based matrix metalloproteinase sequestering biomaterial in vivo.
    Khan OF; Jean-Francois J; Sefton MV
    J Biomed Mater Res A; 2010 Jun; 93(4):1368-79. PubMed ID: 19911383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
    Puerta DT; Lewis JA; Cohen SM
    J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases.
    Faust A; Waschkau B; Waldeck J; Höltke C; Breyholz HJ; Wagner S; Kopka K; Schober O; Heindel W; Schäfers M; Bremer C
    Bioconjug Chem; 2009 May; 20(5):904-12. PubMed ID: 19374404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new role for old ligands: discerning chelators for zinc metalloproteinases.
    Jacobsen FE; Lewis JA; Cohen SM
    J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adsorption of matrix metalloproteinases onto biomedical polymers: a new aspect in biological acceptance.
    Renò F; Traina V; Cannas M
    J Biomater Sci Polym Ed; 2008; 19(1):19-29. PubMed ID: 18177551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
    Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
    J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
    Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.
    Rossello A; Nuti E; Catalani MP; Carelli P; Orlandini E; Rapposelli S; Tuccinardi T; Atkinson SJ; Murphy G; Balsamo A
    Bioorg Med Chem Lett; 2005 May; 15(9):2311-4. PubMed ID: 15837315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity-based matrix metallo-protease enrichment using automated, inhibitor affinity extractions.
    Freije JR; Klein T; Ooms JA; Franke JP; Bischoff R
    J Proteome Res; 2006 May; 5(5):1186-94. PubMed ID: 16674108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
    Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
    Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo.
    Breyholz HJ; Wagner S; Levkau B; Schober O; Schäfers M; Kopka K
    Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):24-32. PubMed ID: 17372570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of an inhibitor-tethered resin for detection of active matrix metalloproteinases involved in disease.
    Hesek D; Toth M; Krchnak V; Fridman R; Mobashery S
    J Org Chem; 2006 Aug; 71(16):5848-54. PubMed ID: 16872162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.
    Oltenfreiter R; Staelens L; Hillaert U; Heremans A; Noël A; Frankenne F; Slegers G
    Appl Radiat Isot; 2005 Jun; 62(6):903-13. PubMed ID: 15799868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid assembly of matrix metalloprotease inhibitors using click chemistry.
    Wang J; Uttamchandani M; Li J; Hu M; Yao SQ
    Org Lett; 2006 Aug; 8(17):3821-4. PubMed ID: 16898826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.
    Kohno T; Hochigai H; Yamashita E; Tsukihara T; Kanaoka M
    Biochem Biophys Res Commun; 2006 May; 344(1):315-22. PubMed ID: 16603129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of folic acid and some matrix metalloproteinase (MMP) inhibitor folate-γ-hydroxamate derivatives with Zn(II) and human serum albumin.
    Enyedy EA; Farkas E; Dömötör O; Santos MA
    J Inorg Biochem; 2011 Mar; 105(3):444-53. PubMed ID: 21421131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Labeling and enrichment of Arabidopsis thaliana matrix metalloproteases using an active-site directed, marimastat-based photoreactive probe.
    Lenger J; Kaschani F; Lenz T; Dalhoff C; Villamor JG; Köster H; Sewald N; van der Hoorn RA
    Bioorg Med Chem; 2012 Jan; 20(2):592-6. PubMed ID: 21775155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.